ReviewReviews in cardiovascular medicine2026
Glutamine Metabolism in Cardiac Hypertrophy.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac hypertrophy represents a crucial adaptive response of the heart to various physiological and pathological stimuli, with metabolic reprogramming serving as the core mechanism driving this process. In recent years, the role of glutamine metabolism in cardiac hypertrophy has garnered increasing attention. This review systematically elucidates the similarities and differences in glutamine metabolism between physiological and pathological cardiac hypertrophy, with a focus on the dual role of glutamine metabolism in regulating cardiomyocyte hypertrophy: it has a protective effect by maintaining energy metabolism and reducing oxidative stress, while simultaneously contributing to the hypertrophic process by promoting anabolic metabolism and exacerbating metabolic remodeling. The subsequent analysis delved into the specific mechanisms by which glutamine metabolism regulates cardiomyocyte hypertrophy, focusing on the functions of key metabolic enzymes and transporters that collectively govern glutamine flux and its downstream signaling pathways. Furthermore, we explore the intricate interplay between glutamine metabolism and lipid metabolism, which plays a pivotal role in cardiac energy homeostasis and hypertrophic development. Finally, we discuss the potential of targeting glutamine metabolism as a therapeutic strategy, highlighting the novel therapeutic prospects of glutamine supplementation in cardiac diseases. In summary, as a key component of metabolic reprogramming in cardiomyocyte hypertrophy, glutamine metabolism offers deeper insights into the pathophysiological mechanisms of cardiac hypertrophy. Future interventions targeting the glutamine metabolic pathway could prevent and treat pathological cardiac hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.